Conclusions

Gradual reperfusion, however, has no more effect than either intervention alone. Gradual reperfusion has no greater effect on mitochondrial permeability pore opening than either intervention alone.

Methods

Anesthetized open-chest rabbits underwent 1.5-h regional ischaemia/1.5-h reperfusion and were divided into four groups: control (C), preconditioning (Pre-con), gradual reperfusion (GR), and preconditioning plus gradual reperfusion (Pre-con + GR). Control hearts underwent no additional intervention. Preconditioning consisted of three cycles of 5 min of ischaemia and 5 min of reperfusion before the 1.5-h ischaemia. Gradual reperfusion hearts underwent 5 stages involving 10-s occlusion/20-s reperfusion, 20-s occlusion/40-s reperfusion, 50-s occlusion/50-s reperfusion, 40-s occlusion/20-s reperfusion, 50-s occlusion/10-s reperfusion starting 10 s after release of the index coronary occlusion. Preconditioning plus gradual reperfusion performed both interventions in preconditioning and gradual reperfusion. 1.5 h reperfusion later, mitochondria were isolated from the risk region myocardium, and mPTP opening was determined by using the mPTP kinetics method.

Results

Preconditioning, and gradual reperfusion alone significantly limited infarct size, which averaged 7.21 \( \pm \) 4.76\% in controls (p < 0.05 vs control). Preconditioning plus gradual reperfusion averaged 7.53 \( \pm \) 3.45\% of left ventricular weigh, respectively, versus 11.94 \( \pm \) 6\% in controls (p < 0.05 vs control). The t\(_{1/2}\) of mPTP kinetics averaged 5.57 \( \pm \) 4.76 min in preconditioning and gradual reperfusion, respectively, significantly higher than the value of 5.06 \( \pm \) 4.76 min in controls (p < 0.05). The t\(_{1/2}\) of mPTP kinetics averaged 6.62 \( \pm \) 4.76 min in preconditioning plus gradual reperfusion, however, has no more effect than preconditioning or gradual reperfusion alone (p > 0.05).

Conclusions

The combination of ischaemic preconditioning and gradual reperfusion has no greater effect on mitochondrial permeability pore but provides more powerful anti-ischaemic protection than either intervention alone.

---

**e0068 INVESTIGATION OF VERAPAMIL IN REVERSING ALTERATIONS OF CELLULAR ELECTROPHYSIOLOGY UNDERLYING VENTRICULAR ARRYTHMIA IN DOGS WITH MULTIPLE ORGAN DYSFUNCTION SYNDROME**

Objective

The mechanism of Verapamil in reversing alterations of cellular electrophysiology underlying ventricular arrhythmia in dogs with multiple organ dysfunction syndrome (MODS) was not reported and their relationship to arrhythmogenesis was likely very limited.

Methods

12 dogs, of weight 8.67 \( \pm \) 0.75 kg, were divided into two groups: control group (n = 6) and MODS group (n = 6). MODS lasting for 72 h was induced. Ventricular myocytes were enzymatically isolated. Early afterdepolarizations (EAD), action potential durations (APD) and L-type calcium currents were assessed before and after Verapamil perfusion.

Results

Sinus arrhythmias in all MODS dogs (100%; 6 of 6, n = 6) and premature ventricular beats in 4 MODS dogs (66%; 4 of 6, n = 6) were recorded, while no arrhythmias were found in control animals. The prolongation of APD associated with decreased L-type Ca\(^{2+}\) currents and frequent provocation of EAD were the typical electrophysiological alterations in myocytes of MODS dogs. The AP prolongation was shortened, L-type calcium currents was decreased, EAD was suppressed by using Verapamil (100 \( \mu \)mol/l) in ventricular myocytes of MODS dogs (66%; 4 of 6, n = 6). EAD could be induced after elusion of Verapamil.

Conclusions

The cellular electrophysiology changes within 72 h in the heart of MODS dogs were APD prolongation, markedly decreased L-type Ca\(^{2+}\) currents as well as frequently provoked EAD. Verapamil appears to be an effective agent in reversing the alterations of cellular electrophysiology in the early stage of MODS.

---

**e0067 ASPIRIN ATTENUATES PULMONARY ARTERIAL HYPERTENSION IN RATS BY REDUCING PLASMA 5-HYDROXYTRYPTAMINE LEVEL**

Shen Lan, Shen Jieyan, Bu Jun, Yuan Ancai. Renji Hospital Shanghai

Pulmonary arterial hypertension (PAH) is characterised by increasing pulmonary pressure, right ventricular failure, and death. The typical pathological changes include medial hypertrophy, intimal fibrosis and in situ thrombosis. 5-HT and other factors contributed to the development of pathologic lesions. Aspirin (ASA), the platelet aggregation inhibitor, inhibits 5-HT release from platelet. The aim of the current study was to determine the efficacy of aspirin in preventing or attenuating pulmonary hypertension. Sprague-Dawley (SD) rats injected with monocrotaline (MCT) at day 0 developed severe PAH at day 31. Rats were randomised to 1. ASA 1 mg/kg/d, ASA 2 mg/kg/d, ASA 4 mg/kg/d. ASA treatment also reduced right ventricular hypertrophy and pulmonary arterioles proliferation. Plasma 5-HT measured by High Performance Liquid Chromatographic (HPLC) was decreased in aspirin treated PAH model.

Conclusions

The prolongation of APD associated with decreased L-type Ca\(^{2+}\) currents as well as frequently provoked EAD. Aspirin treatment also reduced right ventricular hypertrophy and pulmonary arterioles proliferation. Plasma 5-HT measured by High Performance Liquid Chromatographic (HPLC) was decreased in aspirin treated PAH model.
respectively, and HR decreased slightly from 125.2±21.3 ms to 102.5±4.94 ms by stimulation of SAN-FP, while HR was not affected by stimulating AVN-FP. The effect of stimulating caval vagus trunk on reducing HR was partially expressed with SAN-FP ablation and totally eliminated by SAN-FP+AVN-FP combined ablation. (2) The ERP and increased ERP dispersion of atrial and pulmonary were significantly by stimulating SAN-FP and abolished by ablating SAN-FP, while no big difference of ERP and ERP dispersion in atrial and pulmonary was recorded when stimulation and ablation was exerted on AVN-FP; (5) Facing at right atrial with 600 bpm, the AF was induced 60% and 18.4% by stimulating right and left caval vagus trunk as well as 15.29% and 2.25% by stimulating SAN-FP and AVN-FP. However, with the stimulating at right and left cervical vagus trunk, the inducibility of AF was reduced to 16.8% and 6% when SAN-FP had ablated and even to 0% when AVN-FP had ablated.

Conclusion We concluded that sinus node function was adjusted mainly by stimulating at right cervical vagus trunk through AVN-FP. The shorted ERP and increased ERP dispersion of atrial and pulmonary as well as AF were induced by stimulating caval vagus trunk mainly coordinated with AVN-FP. Our study strongly suggested that AVN-FP is a very important coordinator in relation to parasympathetic dominant AF.

**e0070** ATORVASTATIN SUPPRESSES INFLAMMATORY RESPONSE INDUCED BY OXLDL THROUGH INHIBITION OF ERK PHOSPHORYLATION, βkBa DEGRADATION AND COX-2 EXPRESSION IN MURINE MACROPHAGES

doi:10.1136/hrt.2010.208967.70

Qin Shao, Lin Hong Shen, Liu Hua Hu, Jun Pu, Ben He. Department of Cardiology, Ren Ji Hospital, Medical School of Shanghai Jiao Tong University, Shanghai, People’s Republic of China

Objective Macrophages crosstalk with oxidised low-density lipoprotein (oxLDL), play a critical role in the initiation, progression and subsequent stability of atherosclerotic plaques. Statins, inhibitors of HMG CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, reduce the expression of inflammatory proteins in addition to their lipid-lowering action. However, the effect and the detailed anti-inflammation mechanisms of statins in macrophages induced by oxLDL remain unclear. In the present study, we investigated the effect of atorvastatin on inflammatory response upon oxLDL stimulation in murine macrophages and analysed the underlying mechanisms.

Methods Raw 264.7 macrophages were cultured and pre-treated with varying doses of atorvastatin in the absence or presence of 40 μg/ml oxLDL. The morphology of the cells was observed and the expression of inflammatory cytokines such as monocyte chemo-attractant protein-1 (MCP-1) and tumour necrosis factor (TNF) was performed by real-time PCR and Western blotting. Atorvastatin and PD98059, inhibitor of ERK1/2 MAPK, the expression of COX-2 was also detected by real-time PCR and Western blotting.

Results Our findings have shown that exposure of RAW264.7 cells to oxLDL, substantially changed the morphology of the cells and increased the mRNA expression of proinflammatory cytokines and chemokines including TNFα and MCP-1, approximately to 14-fold, 10-fold, respectively while pretreatment with atorvastatin resulted in a significant inhibition of the oxLDL-induced morphological alteration and inflammatory cytokines expression in a dose-dependent fashion. Further investigation of the molecular mechanism revealed that oxLDL upregulated the transcription and protein expression of COX-2 in a time-dependent manner. Moreover, the activation of ERK pathway and βkBa degradation contribute to this effect.

Conclusions Taken together, the anti-inflammatory effect of atorvastatin is mediated through the inhibition of proinflammatory COX-2. Furthermore, suppression of ERK phosphorylation and βkBa degradation is involved in this regulation. Our findings provide novel evidence that statins suppress inflammatory response in murine macrophages induced by oxLDL, exert its anti-atherogenic actions via against inflammation beyond cholesterol-lowering effect.

**e0071** EFFECT OF FLUVASTATIN ON MYOCARDIAL INTERSTITIAL FIBROSIS AND CARDIAC FUNCTION IN DIABETIC RATS

doi:10.1136/hrt.2010.208967.71

Dai Qiming, Liu Naifeng, Zhong Da Hospital

Objective To investigate effect of fluvastatin on myocardial interstitial fibrosis and cardiac function in diabetic rats.

Methods 24 male SD rats were randomly divided into three groups: normal control (n=8), untreated and STZ-induced diabetic rats (n=8) and diabetic rats treated with fluvastatin (n=8). DM was induced in male SD rats with a single intraperitoneal (i.p.) injection of streptozotocin 50 mg/kg dissolved in 20 ml citrate buffer (pH 4.5) overnight. Tail vein blood glucose was measured 72 h later and those with plasma glucose levels ≥16.7 mmol/l were considered to be diabetic. Control rats were injected 1 ml/kg body weight of 20 ml citrate buffer (pH 4.5) vehicle, and diabetic rats were treated with fluvastatin (10 mg/kg administered orally, n=8). Fluvastatin were dissolved in sterile water, and administered every day via stomach tube. These rats were housed for 12 weeks with daily general checking. After 12 weeks intervention, miniature cardiac catheter was inserted into the left ventricle to conduct haemodynamic examination. Then, myocardium tissues were collected, collagen content was detected by picro-sirius red staining, immunohistochemistry was used to detect protein expression of fibronectin, real-time RT-PCR was used to detect the mRNA expression of CTGF and Western blotting was used to detect the protein expression of CTGF. RhoA activity in LV myocardial tissue of rats was determined by pull down assay.

Results By the end of the experiment, the left ventricular systolic pressure (LVSP)(97±12 mm Hg vs 131±21 mm Hg) and maximum rate of left ventricular (LV) pressure rise and fall (+dP/dt max and -dP/dt max) (4410±332 mm Hg/s vs 6465±442 mm Hg/s and -4326±365 mm Hg/s vs 6432±426 mm Hg/s) were significantly lower and left ventricular end diastolic pressure (LVEDP) (16.2±3.2 mm Hg vs 4.8±1.2 mm Hg) were significantly higher in the diabetic group compared to the control group (all =0.01). Moreover, in LV myocardial tissue of diabetic rats the collagen content (4.2%±0.56% vs 6.4%±0.33%, p<0.01), fibronectin (3.12±0.30 vs 0.95±0.33, p<0.01), mRNA and protein expression of CTGF (0.86±0.10 vs 1.37±0.24 and 0.48±0.13 vs 1.26±0.22, p<0.01) and the activity of RhoA (1.72±0.21 vs 1.1±0.1, p<0.01) were all significantly increased compared to the control rats. Administration of fluvastatin obviously improved the cardiac function of diabetic rats, attenuated fibronectin expression, mRNA and protein expression of CTGF and the activity of RhoA in LV myocardium of diabetic rats.

Conclusions Our data demonstrate that fluvastatin attenuates cardiac dysfunction and myocardial interstitial fibrosis of diabetic rat by inhibiting activity of RhoA to down-regulate the over-expression of CTGF, and Rho/Rho-kinase pathway may be an important target in the treatment of diabetic cardiomyopathy.